- Open Access
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy
- Jiunn-Jye Sheu†1,
- Pao-Yuan Lin†2,
- Pei-Hsun Sung3,
- Yi-Ching Chen3,
- Steve Leu4,
- Yung-Lung Chen3,
- Tzu-Hsien Tsai3,
- Han-Tan Chai3,
- Sarah Chua3,
- Hsueh-Wen Chang5,
- Sheng-Ying Chung3,
- Chih-Hung Chen6,
- Sheung-Fat Ko7Email author and
- Hon-Kan Yip3, 4, 8Email author
© Sheu et al.; licensee BioMed Central Ltd. 2014
- Received: 30 October 2013
- Accepted: 31 March 2014
- Published: 17 April 2014
We tested the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction, facilitate proliferation of circulating endothelial progenitor cell (EPC), and improve the clinical outcomes of critical limb ischemia (CLI) in patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA).
A total 55 patients (mean age, 72 years; 56% female) were consecutively enrolled. Clopidogrel and cilostazol combination therapy was administered throughout the study period.
As compared with the baseline, circulating endothelial progenitor cell level (as shown by flow cytometry) was significantly increased (p < 0.003), whereas the CLI-related ulcers and painfulness were significantly improved (all p < 0.01) by day 90 after treatment. On the other hand, after clopidogrel and cilostazol combination therapy, galectin-3 level, lipoprotein-associated phospholipase A2 gene expression, and RhoA/ROCK-related protein expression in peripheral blood mononuclear cells were significantly suppressed (all p < 0.01). Eventually, by day 90, 5 patients (9.1%) died of other etiologies, 3 (5.5%) withdrew from the study, 6 (10.9%) required amputation, and the remaining 41 had satisfactory clinical improvement with complete wound healing in 9 (16.4%) patients.
The results of the present study highlight that clopidogrel and cilostazol combination therapy may be considered to be an alternative method for treating patients with CLI unsuitable for surgical revascularization or PTA.
- Critical limb ischemia
- Endothelial progenitor cells
- Cilostazol therapy
Atherosclerosis is a progressive and complex inflammatory process affecting both regional and systemic arteries[1–5]. Peripheral artery disease (PAD) caused by atherosclerotic lesions is an important manifestation of systemic atherosclerosis. Patients with PAD may develop critical limb ischemia (CLI) at the late stage of the disease[7, 8]. Treatment for CLI remains a tough challenge to clinicians. Without appropriate treatment, the 1-year mortality rate can be as high as 25%. Failure in salvaging CLI can lead to major limb loss and high cost of patient care following amputation. Although surgical or endovascular revascularization have been used for the treatment of CLI with acceptable successful rate, for the patients who are not good candidates for surgical or endovascular intervention and those with failure of revascularization or bypass occlusion, the clinical outcomes remain dismal. Therefore, an alternative strategy for the treatment of such CLI patients is necessary.
Platelet activation and inflammation have been reported to play essential roles in the development of arterial atherosclerotic-obstructive syndrome (AAOS)[1–5, 10–13]. Various biomarkers have been used for assessing platelet activity and inflammation in different clinical settings. Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase, is useful for predicting unfavorable outcome in patients after acute ischemic stroke[14–16]. Galectin-3, a biomarker of inflammatory response, is a useful predictor of prognostic clinical outcome in patients after acute myocardial infarction (AMI)[17–22]. Rho, a small monomeric GTPase, and Rho-associated kinases (ROCK), the immediate downstream targets of RhoA, are useful for monitoring sustained vasoconstriction, vascular remodeling, and inflammatory response in arterial obstructive diseases[23–27] as well as down-regulation and inhibition of endothelial nitric oxide synthase (eNOS)[28, 29].
Clopidogrel, an adenosine diphosphatase (ADP) inhibitor, is currently utilized in acute arterial occlusive syndrome[10, 30], after coronary artery stenting for inhibiting platelet activity and in-stent thrombus formation, and in secondary prevention and at high-risk prevention for atherothrombotic events[31, 32]. Cilostazol, a phosphodiesterase III inhibitor for treating intermittent claudication owing to its pleotropic effects in reducing smooth muscle proliferation, limiting intimal hyperplasia after endothelial injury, inhibiting platelet activation and thrombus formation, and heightening anti-inflammation[33–35]. The purpose of this study was to test the hypothesis that clopidogrel and cilostazol combination therapy could effectively attenuate systemic inflammatory reaction through inhibiting Lp-PLA2 activity, galectin-3 and Rho/ROCK, facilitate mobilization of circulating endothelial progenitor cell (EPC) to circulation, and improve the clinical outcomes of CLI patients unsuitable for surgical revascularization or percutaneous transluminal angioplasty (PTA).
Between September 2010 and October 2012, a total 55 CLI patients who fulfilled the following criteria were enrolled. Inclusion criteria of the patients included: (a) presence of Fontaine stage III-IV CLI presented with ischemic rest pain and ischemic skin lesions, either ulcers or gangrene; (b) featuring a reduced ankle-brachial index (ABI) less than 0.9 at rest and ankle systolic pressure less than 50 mmHg; (c) harboring diffuse long segmental infrapopliteal severe stenoses or occlusion and marked narrowing or lack of pedal arteries so that the patients were determined as not appropriate for surgical or endovascular interventions. The enrolled candidates were then managed with clopidogrel (75 mg/day) and cilostazol (50 mg twice per day) combination therapy. Patients who had allergy to the drug or hematologic disorder or bleeding/hemostatic problem and refused the treatment were excluded from the study. The Institutional Review Committee on Human Research at our institution approved this study protocol (the IBR number: 99-1688B) and informed consent was obtained from each study subject.
Definition of ulceration wound and grade on healing
Wound grade 1: defined as partial thickness involving only dermis and epidermis
Wound grade 2: defined as full thickness and subcutaneous tissues
Wound grade 3: defined as grade 2 plus exposed tendons, ligament, and/or joint
Wound grade 4: defined as grade 3 plus abscess and/or osteomyelitis
Wound grade 5: defined as grade 3 plus necrotic tissue in wound
Wound grade 6: defined as grade 3 plus gangrene in the wound and surrounding tissue
Blood samples for the assessments of circulating galectin-3 level and the Rho/ROCK activity and Lp-PLA2 gene expression in peripheral-blood mononuclear cells (PBMNCs) were collected via the antecubital vein prior to and at 90 day after the drug therapy.
Measurement of galectin-3 level
After centrifugation, the aliquot of the samples was stored at -80°C before the assay for galectin-3 level. White blood cell (WBC) counts, biochemical measurements and electrolyte levels were performed with standard laboratory methods. Serum galectin-3 level was measured by duplicated determination with a commercially available ELISA method (R & D). The intra-observer variability of the measurements of galectin-3 levels was also assessed and the mean intra-assay coefficients of variance were all < 4.6%.
Protocol for RNA extraction and reverse transcription qPCR analysis for relative mRNA expression of Lp-PLA2 of PBMNCs to β actin
The procedure and protocol for RNA extraction reverse transcription qPCR analysis were according to our previous report. In details, the lysis/binding buffer (400 μL) (High Pure RNA Tissue Kit, Roche, Germany) and an appropriate amount of frozen PBMNCs were added to a nuclease-free 1.5 mL microcentrifuge tube, followed by disruption and homogenization of BPMNCs by using a rotor-stator homogenizer (Roche). The lysate in the microcentrifuge tube was then centrifuged for two minutes at 13,000 g. Only the superficially collected supernatant was utilized for subsequent steps. Absolute ethanol (200 μL) was then added to the lysate supernatant and mixed well. The entire sample in the upper reservoir was pipetted into a High Pure Filter Tube (Roche) that was placed in the Collection Tube (Roche). This sample was then centrifuged for 30 seconds at 13,000 g in a standard tabletop microcentrifuge. After that, the Filter Tube was removed from the Collection Tube and the flowthrough liquid was discarded. For each isolation, 90 μL of DNase incubation buffer was pipetted into a sterile 1.5 mL reaction tube, 10 μL of DNase I working solution was then added, mixed and incubated for 15 minutes at 25°C. Wash buffer I (500 μL) was then added to the upper reservoir of the filter tube, which was then centrifuged for 15 seconds at 8,000 g. The filter tube was removed from the Collection Tube and the flowthrough liquid was then discarded. Wash Buffer II (500 μL) was added to the upper reservoir of the Filter Tube, which was then centrifuged for 15 seconds at 8,000 g and the flowthrough was discarded. Wash buffer II (300 μL) was added to the upper reservoir of the filter tube, which was centrifuged for 2 minutes full-speed at approximately 13,000 g. The column was then carefully removed from the collection tube such that the column did not contact the flow through to avoid ethanol carryover. The filter tube was then inserted into a 1.5 mL nuclease-free and sterilized microcentrifuge tube. Elution Buffer (100 μL) was added to the upper reservoir of the filter tube; the tube assembly was then centrifuged for 1 minute at 8,000 g resulting in eluted RNA in the microcentrifuge tube.
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was conducted using LightCycler TaqMan Master (Roche, Germany) in a single capillary tube according to the manufacturer’s guidelines for individual component concentrations. The Lp-PLA2 forward (TGGCTTACCTTAGAACCCTGA) and reverse (TTTTGCTCTTTGCCGTACCT) primers were each designed based on individual exons of the target gene sequence to avoid amplifying genomic DNA.
During PCR, the probe was hybridized to its complementary single-strand DNA sequence within the PCR target. As amplification occurred, the probe was degraded due to the exonuclease activity of Taq DNA polymerase, thereby separating the quencher from reporter dye during extension. During the entire amplification cycle, light emission increased exponentially. A positive result was determined by identifying the threshold cycle value at which reporter dye emission appeared above the background.
Western lot analysis of PBMNC specimens for Rho/ROCK activity
Equal amounts of extracted proteins from BPMNCs in each patient were loaded and separated by SDS-PAGE using 7% or 12% acrylamide gradients. The membranes were incubated with rabbit polyclonal antibodies against myosin phosphatase (MYPT), p-MYPT, myosin light chain, p-MLC, and small GTP-binding proteins: (1) RhoA, (2) Rac.
Proteins were transferred to nitrocellulose membranes which were then incubated in the primary antibody solution (anti-DNP 1:150) for two hours, followed by incubation with the second antibody solution (1:300) for one hour at room temperature. The washing procedure was repeated eight times within 40 minutes.
Immunoreactive bands were visualized by enhanced chemiluminescence (ECL; Amersham Biosciences), which was then exposed to Biomax L film (Kodak). For quantification, ECL signals were digitized using Labwork software (UVP). For oxyblot protein analysis, a standard control was loaded on each gel.
Flow cytometric analysis for circulating endothelial cells (EPCs)
A flow cytometic method for identification of EPCs derived from peripheral blood has been reported in our recent studies and also those by others. Briefly, the isolated MNCs (4 × 105) were incubated for 30 minutes at 4°C in a dark room with monoclonal antibodies against kinase insert domain-conjugating receptor (KDR) (Sigma), the fluorescein isothiocyanate (FITC)-conjugated CD34 and the phycoerythrin (PE)-conjugated CD31, and CXCR4 to determine the EPC surface markers of CD31/CD34, CXCR4/CD34, and KDR/CD34. The control ligand (IgG-PE conjugate) was used to detect any nonspecific association and define a threshold for glycoprotein binding. For analysis of KDR, the MNCs were further incubated with PE-conjugated anti-mouse antibody made in goat. After staining, the MNCs were fixed in 1% of paraformaldehyde. Quantitative two-colored flow cytometric analysis was performed using a fluorescence-activated cell sorter (FACSCalibur™ system; Beckmen). Each analysis included 300,000 cells per sample. The assays for EPCs (E1–3) in each sample were performed in duplicate, with the mean level reported.
For the accuracy of flow cytometry, we had performed both isotype control and fluorescence minus one (FMO) control for each sample of flow cytometric examination. The results showed that only none or lesser than 0.1% of fluorescence spillover in each FMO control test.
Intra-assay variability based on repeated measurement of the same blood sample was low with a mean coefficient of variance being 3.9% and 3.6% in the patients and in normal subjects, respectively.
Chest radiographs, duplex scanning for assessing the arterial flow of lower extremity, 12-lead electrocardiogram, echocardiography, at least one time of magnetic resonance angiography image (MRA) or digital subtraction angiography of the lower extremities were performed upon hospitalization or at out patient department for evaluating the severity of obstructive arteries in the lower extremity.
In addition to cilostazol and clopidogrel combination therapy, other commonly used drugs including statin, angiotensin converting enzyme inhibitors, calcium channel blocking agents, and isordil/vasodilatation agents were applied as needed by individual.
Data collection and clinical follow-up
Detailed in-hospital and follow-up data at out patient department including age, gender, coronary risk factors, serum creatinine level and other related laboratory findings, adverse clinical events during study period and mortality were obtained.
Continuous variables with normal distribution were expressed as mean ± SD. Categorical data were analyzed by Chi-square test and continuous variables were analyzed using paired t test. Statistical analysis was performed using SPSS statistical software for Windows version 13 (SPSS for Windows, version 13; SPSS Inc., IL, U.S.A.). A p-value of < 0.05 was considered statistically significant.
Baseline characteristics of 55 study patients
Baseline characteristics of 55 study patients
% (n) or mean ± SD
72 ± 11
Chronic kidney disease (stage I-IV)
End-stage renal disease on regular hemodialysis
History of one leg amputation
Compared the changes of laboratory findings, circulating EPC and galectin-3 level, and Lp-PLA2 mRNA expression between day 0 and day 90 after clopidogrel and cilostazol combination therapy among 55 study patients
Comparison of laboratory findings, circulating galectin-3 level and Lp-PLA2 gene expression between day 0 and day 90 after combined clopidogrel and cilostazol treatment among 55 study patients
Red blood cell count (×106)
4.0 ± 0.8
3.8 ± 0.7
White blood cell count (×103)
8.2 ± 3.2
8.0 ± 2.2
Platelet count (×103)
250 ± 78
236 ± 115
11.5 ± 2.1
11.1 ± 2.1
Total cholesterol level
181 ± 52
152 ± 22
106 ± 43
79 ± 24
55 ± 14
58 ± 14
Creatinine level (mg/dL)
3.23 ± 3.31
3.35 ± 3.46
158 ± 76
148 ± 41
7.28 ± 1.65
6.80 ± 0.92
1.46 ± 0.10
1.37 ± 0.09
23.09 ± 4.17
15.53 ± 4.33
0.77 ± 0.48
0.80 ± 0.56
0.84 ± 0.55
0.89 ± 0.39
1.10 ± 0.70
1.11 ± 0.89
The Ac sugar and creatinine level did not differ between day 0 and day 90 among these patients. However, as compared with day 0, the HbA1c levels were significantly reduced by day 90 after the combination therapy with clopidogrel and cilostatzol. Additionally, as compared with baseline, the circulating galectin level and the mRNA expression of Lp-PLA2, two indices of inflammatory biomarkers, were significantly lower by day 90 after clopidogrel and cilostazol combination therapy.
To elucidate whether the circulating numbers of EPCs (i.e., CD31+/CD34+, KDR+/CD34+, CXCR4+/CD34+) would be increased after clopidogrel and cilostazol combination therapy and statin, these circulating EPCs were measured using flow cytometry. As expected, these three surface EPC markers were significantly higher at day 90 than after these drug therapy than at day 0 prior to the treatment.
Compared the protein expressions of RhoA/ROCK-related signaling between baseline and day 90 after the treatment
Clinical outcomes on day 90
90-Day clinical outcomes among 55 study patients
Mean ulcerative wound (grading)
2.90 ± 1.60
2.11 ± 1.64
Painful sensation due to CLI
90-day individual clinical outcome
Gastric ulcer with bleeding
Status of CLI (90-day end point)
Amputation due to worsening CLI
During the study period, one patient experienced gastric ulcer with bleeding and the requirement of blood transfusion. By day 90, 6 patients had to receive toe amputation due to worsening CLI. On the other hand, 19 patients had a stationary setting of CLI, 13 patients had greater improvement of CLI condition and 9 patients had complete healing of the CLI. Loss of follow-up was noted in three patients. Five patients died during the study period, including three with sepsis and shock, one with severe cardiovascular insult, and one with colon cancer.
This study, which investigated the impact of clopidogrel and cilostazol combination therapy on 90-day clinical outcome of 55 high-grade CLI patients unsuitable for surgical revascularization or PTA, yielded several striking implications. First, wound healing was remarkably improved, whereas the painfulness owing to ischemia-related ulcers was markedly reduced by day 90 after clopidogrel and cilostazol combination therapy. Second, after combination therapy, only few patients required the amputation treatment. Third, galectin-3 level, Lp-PLA2 gene expression, and RhoA/ROCK-related protein expression in PBMNCs, three indexes of inflammation, were substantially suppressed, whereas circulating EPC number was notably increased on day 90 after combination therapy. Accordingly, the results of the present study highlight that clopidogrel and cilostazol combination therapy may be considered as an alternative method for treating high-grade CLI patients with no surgical or endovascular revascularization.
A strong association between inflammation and atherosclerosis and acute arterial occlusive syndrome has been extensively investigated[1–5, 10, 13, 16]. One recent study has shown that circulating level of galectin-3, an inflammatory biomarker, was significantly increased in patients after AMI and is useful for predicting untoward clinical outcome in AMI patients undergoing primary coronary intervention. The present study also reveals marked elevation of galectin-3 level in patients with high-grade CLI suggesting that in addition to acute coronary arterial obstruction, galectin-3 can also be regarded as a biomarker for assessing chronic arterial ischemia. Of note, the circulating level of this biomarker was significantly suppressed at day 90 after clopidogrel and cilostazol combination therapy.
In the present study, in order to evaluate the role of WBC in the inflammatory process under the clinical setting of CLI, besides circulating level of galectin-3, the cellular level of inflammation in both mRNA expression (i.e., transcription level, i.e., Lp-PLA2) and protein express (translation level, i.e., RhoA/ROCK) were prospectively assessed. Interestingly, our recent study has displayed that Lp-PLA2 mRNA expression of PBMNC was significantly elevated in patients after acute ischemic stroke and elevated Lp-PLA2 mRNA expression can predict unfavorable outcome in such patients. In addition to occlusion of the cerebral arteries, our results also show markedly elevated level of Lp-PLA2 mRNA expression in PBMNCs in CLI patients with peripheral arterial occlusion. In this way, our present finding strengthens that of our recent study. Of particular importance was that this gene expression in PBMNCs was significantly attenuated by day 90 after clopidogrel and cilostazol combination therapy. Based on the present study, we postulate that galectin-3 and Lp-PLA2 mRNA may also be valuable biomarkers for assessing acute and chronic inflammatory changes.
A body of previous studies have shown that ROCK signaling pathway mediates in the sustained vasoconstriction, smooth muscle proliferation, vascular remodeling, hypertension and inflammatory reaction[23, 27, 38] and participates in down-regulation and inhibition of endothelial nitric oxide synthase (eNOS)[28, 29]. Additionally, abundant evidences have revealed that peripheral leukocyte ROCK activity is an useful biomarker for predictive of co-morbidity of cardiovascular disease and long-term mortality in patients with cardiovascular disease[39, 40]. In the present study, as compared with the baseline, our results reveal that the protein expressions of RhoA and Tac (two small GTP-binding proteins which mediates the pathological process of ROCK) were remarkably reversed whereas the total MLC and phosphorylated MLC (indicator of ROCK activity), and the ratio of phosphorylated MLC to total MLC were substantially attenuated on day 90 after clopidogrel and cilostazol combination therapy. These findings imply that combination therapy may have reduced the pro-inflammatory effect of WBCs despite no change in WBC counts between days 0 and 90 of study period (Table 2).
Clinical observational study have previously demonstrated that the 1-year mortality rate can be as high as 25% for CLI patients without appropriate treatment. The most important finding in the present study was that besides marked suppression on inflammatory biomarkers, the clinical outcome of our patients with high-grade CLI without surgical or endovascular intervention was notably improved after clopidogrel and cilostazol combination therapy. Additionally, the blood sugar, HbA1c, total cholesterol level and LDL were also markedly reduced on day 90. Therefore, we suggest that the 90-day clinical improvement in CLI patients could be due to not only the effect of combination therapy but was also due to the well control of traditional CAD risk factors. The COURAGE Trial has emphasized the clinical outcome of optimal medical therapy without percutaneous coronary intervention (PCI) in patients with stable coronary artery disease is similar to those underwent PCI on long-term follow-up. The results from Courage study may support the findings of our study. Therefore, in view of the previous study outcomes[9, 40], the results of the present study encourage the use of clopidogrel and cilostazol combination therapy for those CLI patients who are not the candidate for surgical or endovascular intervention.
The exact mechanisms of clopidogrel and cilostazol combination therapy in CLI remain unclear. We propose that three effects might be generated. First, marked clinical improvement with resumption of distal blood flow could be observed in our patients (Figure 1) indicating enhancement of vascularities in the lower extremities after treatment. Concurred with a recently published article with significantly enhanced angiogenesis and number of EPCs in the ischemic zone in a rat CLI model after combination therapy, remarkably elevation of the circulating level of EPCs was found in our patients after similar treatment for 90 days. Second, studies have previously reported that proliferation of neo-intimal growth of vascular smooth muscle cells (i.e., neointimal hyperplasia) plays a key role in the progression of restenosis and PAD as well as restenosis after PAD intervention[43–45]. Additionally, as described in many studies clopidogrel and cilostazol harbor anti-platelet and anti-thrombotic effects while cilostazol can inhibit smooth muscle cell proliferation[10, 30–35]. According to the results of these studies[10, 30–35, 43–45], we believe that such effects may also contribute to the delightful outcome of among our patients. Third, as revealed by our results, clopidogrel and cilostazol combination therapy elicit potent anti-inflammatory effect which is helpful in limiting the exacerbation of ulcers and augmenting would healing.
Platelet activation in setting of CLI stimulated the activation and migration of peripheral leukocytes (i.e., macrophages and T-cell). Both activated macrophages and T-cells then produced the galactin-3 which, in turn, promoted the focal adhesion turnover, cell migration, and RhoA activation. Additionally, Lp-PLA2 enhanced the generation of inflammatory cytokines and up-regulated the inflammatory process. Finally, galactin-3, Lp-PLA2 and RhoA/ROCK synergistically promoted the inflammation and ultimately worsened the wound ulcerations and painful sensation (Figure 5). On the other hand, combine therapy with clopidogrel and cilostazol enhanced angiogenesis/neovascularization which, in tern, improve blood flow in the ischemia zone, and finally, improved the wound healing.
This study has limitations. First, the sample size of the present study was relatively small. However, the preliminary results clopidogrel and cilostazol combination therapy in CLI patients who are not amendable by surgical or endovascular methods are promising. Second, the 90-day study period in this initial trial was relatively short. The clinical benefits or drawbacks after long-term combination therapy are not known. Third, in addition to clopidogrel and cilostazol combination therapy, patients were also subjected to statin and ACI/ARB treatment during the study period and thus the effects or interaction of these drugs could hardly be validated. Fourth, although the methodology of EPC measurement in the present study was based on a validated method, a two-color assay with each of CD31, CXCR4 and KDR evaluated against CD34 might not accurately enumerate all of the EPCs. Finally, this study did not provide a placebo or control group. Therefore, we did not provide accurate information for how much additional benefit that the patients actually gained after receiving the combined treatment.
In conclusion, the results of the present study highlight that clopidogrel and cilostazol combination therapy may be considered as an alternative method for treating CLI patients who were not appropriate candidates for surgical revascularization or PTA.
This study was supported by a program grant from Chang Gung Memorial Hospital, Chang Gung University (Grant number: CMRPG891501 and CMRPG891502).
- Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993, 362: 801-809. 10.1038/362801a0.View ArticlePubMedGoogle Scholar
- van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994, 89: 36-44. 10.1161/01.CIR.89.1.36.View ArticlePubMedGoogle Scholar
- Ross R: Atherosclerosis–an inflammatory disease. N Engl J Med. 1999, 340: 115-126. 10.1056/NEJM199901143400207.View ArticlePubMedGoogle Scholar
- Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, Fu M: Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest. 2004, 126: 1417-1422. 10.1378/chest.126.5.1417.View ArticlePubMedGoogle Scholar
- Yip HK, Wu CJ, Yang CH, Chang HW, Fang CY, Hung WC, Hang CL: Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting. Circ J. 2005, 69: 890-895. 10.1253/circj.69.890.View ArticlePubMedGoogle Scholar
- Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001, 344: 1608-1621. 10.1056/NEJM200105243442108.View ArticlePubMedGoogle Scholar
- Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001, 286: 1317-1324. 10.1001/jama.286.11.1317.View ArticlePubMedGoogle Scholar
- Ouriel K: Peripheral arterial disease. Lancet. 2001, 358: 1257-1264. 10.1016/S0140-6736(01)06351-6.View ArticlePubMedGoogle Scholar
- Dormandy J, Heeck L, Vig S: The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999, 12: 142-147.PubMedGoogle Scholar
- Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, Chang YY, Lai SL, Chen WH, Chen MC: Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke. 2004, 35: 1683-1687. 10.1161/01.STR.0000131658.80951.c3.View ArticlePubMedGoogle Scholar
- Yip HK, Chang LT, Sun CK, Chen MC, Yang CH, Hung WC, Hsieh YK, Fang CY, Hang CL, Wu CJ, Chang HW: Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J. 2006, 70: 31-36. 10.1253/circj.70.31.View ArticlePubMedGoogle Scholar
- Yip HK, Lu CH, Yang CH, Chang HW, Hung WC, Cheng CI, Chen SM, Wu CJ: Levels and value of platelet activity in patients with severe internal carotid artery stenosis. Neurology. 2006, 66: 804-808. 10.1212/01.wnl.0000208220.04165.05.View ArticlePubMedGoogle Scholar
- Libby P, Geng YJ, Sukhova GK, Simon DI, Lee RT: Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci. 1997, 811: 134-142. 10.1111/j.1749-6632.1997.tb51996.x. discussion 142–135View ArticlePubMedGoogle Scholar
- Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM: Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem. 1990, 265: 9682-9687.PubMedGoogle Scholar
- Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K: Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999, 261: 511-514. 10.1006/bbrc.1999.1066.View ArticlePubMedGoogle Scholar
- Tsai TH, Chen YL, Lin HS, Liu CF, Chang HW, Lu CH, Chang WN, Chen SF, Wu CJ, Leu S, Ko SF, Yip HK: Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J Atheroscler Thromb. 2012, 19: 523-531. 10.5551/jat.10751.View ArticlePubMedGoogle Scholar
- Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994, 269: 20807-20810.PubMedGoogle Scholar
- Cooper DN: Galectinomics: finding themes in complexity. Biochim Biophys Acta. 2002, 1572: 209-231. 10.1016/S0304-4165(02)00310-0.View ArticlePubMedGoogle Scholar
- Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008, 172: 288-298. 10.2353/ajpath.2008.070726.PubMed CentralView ArticlePubMedGoogle Scholar
- Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000, 275: 2247-2250. 10.1074/jbc.275.4.2247.View ArticlePubMedGoogle Scholar
- de Boer RA, Yu L, van Veldhuisen DJ: Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010, 7: 1-8. 10.1007/s11897-010-0004-x.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, Ko SF, Yip HK: Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012, 19: 1073-1082. 10.5551/jat.12856.View ArticlePubMedGoogle Scholar
- Noma K, Oyama N, Liao JK: Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol. 2006, 290: C661-C668.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S: ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392: 189-193. 10.1016/0014-5793(96)00811-3.View ArticlePubMedGoogle Scholar
- Wei L, Roberts W, Wang L, Yamada M, Zhang S, Zhao Z, Rivkees SA, Schwartz RJ, Imanaka-Yoshida K: Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development. 2001, 128: 2953-2962.PubMedGoogle Scholar
- Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992, 70: 389-399. 10.1016/0092-8674(92)90163-7.View ArticlePubMedGoogle Scholar
- Wojciak-Stothard B, Williams L, Ridley AJ: Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 1999, 145: 1293-1307. 10.1083/jcb.145.6.1293.PubMed CentralView ArticlePubMedGoogle Scholar
- Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998, 273: 24266-24271. 10.1074/jbc.273.37.24266.View ArticlePubMedGoogle Scholar
- Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z: Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002, 22: 8467-8477. 10.1128/MCB.22.24.8467-8477.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Yip HK, Wu CJ, Hang CL, Chang HW, Hung WC, Yeh KH, Yang CH: Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation. Circ J. 2005, 69: 1208-1211. 10.1253/circj.69.1208.View ArticlePubMedGoogle Scholar
- Ferreiro JL, Bhatt DL, Ueno M, Bauer D, Angiolillo DJ: Impact of Smoking on Long-Term Outcomes in Patients with Atherosclerotic Vascular Disease Treated with Aspirin or Clopidogrel: Insights from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Trial. J Am Coll Cardiol. 2014, 63: 769-777. 10.1016/j.jacc.2013.10.043.View ArticlePubMedGoogle Scholar
- Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic R, Ischemic Stabilization M, Avoidance Executive C: Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004, 148: 263-268. 10.1016/j.ahj.2004.03.028.View ArticlePubMedGoogle Scholar
- Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB: Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994, 48: 827-835.View ArticlePubMedGoogle Scholar
- Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, Sakaguchi S, Yoshioka T, Ohishi H, Kimura Y, Yoshikawa T: Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol. 1995, 30: 532-537. 10.1097/00004424-199509000-00004.View ArticlePubMedGoogle Scholar
- Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS, Cliostazol for restonsis trial (CREST) investigators: Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005, 112: 2826-2832. 10.1161/CIRCULATIONAHA.104.530097.View ArticlePubMedGoogle Scholar
- Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA: Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care. 2002, 25: 1835-1839. 10.2337/diacare.25.10.1835.View ArticlePubMedGoogle Scholar
- Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW: Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke. 2008, 39: 69-74. 10.1161/STROKEAHA.107.489401.View ArticlePubMedGoogle Scholar
- Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A: Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001, 15: 1062-1064.PubMedGoogle Scholar
- Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK: Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009, 119: 131-138. 10.1161/CIRCULATIONAHA.108.813311.PubMed CentralView ArticlePubMedGoogle Scholar
- Dong M, Liao JK, Fang F, Lee AP, Yan BP, Liu M, Yu CM: Increased Rho kinase activity in congestive heart failure. Eur J Heart Fail. 2012, 14: 965-973. 10.1093/eurjhf/hfs068.PubMed CentralView ArticlePubMedGoogle Scholar
- Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS, COURAGE trial investigators: Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol. 2009, 104: 1-4. 10.1016/j.amjcard.2009.02.059.View ArticlePubMedGoogle Scholar
- Sheu JJ, Lin KC, Tsai CY, Tsai TH, Leu S, Yen CH, Chen YL, Chang HW, Sun CK, Chua S, Yang JL, Yip HK: Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. J Transl Med. 2012, 10: 164-10.1186/1479-5876-10-164.PubMed CentralView ArticlePubMedGoogle Scholar
- Chan YC, Cheng SW: Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. Int J Clin Pract. 2011, 65: 664-668. 10.1111/j.1742-1241.2011.02639.x.View ArticlePubMedGoogle Scholar
- Buechel R, Stirnimann A, Zimmer R, Keo H, Groechenig E: Drug-eluting stents and drug-coated balloons in peripheral artery disease. Vasa. 2012, 41: 248-261. 10.1024/0301-1526/a000200.View ArticlePubMedGoogle Scholar
- Mongiardo A, Curcio A, Spaccarotella C, Parise S, Indolfi C: Molecular mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy. Curr Drug Targets Cardiovasc Haematol Disord. 2004, 4: 275-287. 10.2174/1568006043336258.View ArticlePubMedGoogle Scholar
- Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, Nabi IR: Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol. 2008, 180: 1261-1275.PubMed CentralPubMedGoogle Scholar
- Gawaz M, Langer H, May AE: Platelets in inflammation and atherogenesis. J Clin Invest. 2005, 115: 3378-3384. 10.1172/JCI27196.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.